FindTrial
Sign In

Efficacy of Cognitive-Behavioral Therapy, in addition to standard systemic methotrexate therapy, in comparison with standard systemic methotrexate alone, in psoriasis

Efficacy of Cognitive-Behavioral Therapy as an adjunct to standard systemic methotrexate therapy, in comparison with standard systemic methotrexate alone, on disease severity, quality of life and biochemical markers of stress in psoriasis: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/08/020823
Enrollment
144
Registered
2019-08-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Cognitive behavourial therapy: Group cognitive behavioral therapy for 40 minutes will be given every fortnight (Total: 6 sessions) for 3 months during their regular follow-up visit to h

Sponsors

Jawaharlal Institute of Postgraduate Medical Education and Research Puducherry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with chronic plaque psoriasis with PASI score more than or equal to 10

Exclusion criteria

Exclusion criteria: Patients with psoriasis with contraindications to methotrexate therapy. Patients with previous history of psychosis. Patients with cognitive impairment.

Design outcomes

Primary

MeasureTime frame
Change in disease severity (PASI) scoreTimepoint: Change in disease severity (PASI) scores will be assessed at each monthly visit for 3 months (0,1,2 and 3 months)—

Secondary

MeasureTime frame
Change in quality of life (DLQI) score and stress (PSLE and DHUS) scores, Change in biochemical markers of stress (CRH, ACTH,cortisol,DHEAS,Prolactin, DHEAS/Cortisol ratio,IL-17,SP, CGRP,Neuropeptide Y)Timepoint: Change in quality of life (DLQI) score and Stress (PSLE and DHUS) scores will be assessed at each monthly visit for 3 months (baseline,1,2 and 3 months). Biochemical markers of stress (CRH, ACTH, cortisol,DHEAS,Prolactin, DHEAS/Cortisol ratio,IL-17,SP, CGRP,Neuropeptide Y) will be assayed at baseline and at 3 months.—

Countries

India

Contacts

Public ContactDr Anna Francis

Jawaharlal Institute of Post graduate Medical Education and Research

linkmedha@gmail.com9486398875

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026